Juul Klaus, Tybjaerg-Hansen Anne, Marklund Stefan, Lange Peter, Nordestgaard Børge G
Department of Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark.
Am J Respir Crit Care Med. 2006 Apr 15;173(8):858-64. doi: 10.1164/rccm.200509-1387OC. Epub 2006 Jan 6.
Increased oxidative stress is involved in chronic obstructive pulmonary disease (COPD); however, plasma and bronchial lining fluid contains the antioxidant extracellular superoxide dismutase. Approximately 2% of white individuals carry the R213G polymorphism in the gene encoding extracellular superoxide dismutase, which increases plasma extracellular superoxide dismutase 10-fold and presumably also renders bronchial lining fluid high in extracellular superoxide dismutase.
We tested the hypothesis that R213G reduces the risk of COPD.
We studied cross-sectionally and prospectively (during 24 yr) 9,258 individuals from the Danish general population genotyped for R213G.
We determined plasma extracellular superoxide dismutase concentration, pulmonary function and COPD diagnosed by means of spirometry or through national hospitalization and death registers.
In the general population, 97.5% were noncarriers, 2.4% were heterozygotes, and 0.02% were homozygotes. Among R213G noncarriers, extracellular superoxide dismutase plasma concentration was 148+/-52 and 142+/-43 ng/ml (mean+/-SD) in individuals with and without COPD (Student's t test, p=0.02). Among heterozygotes, corresponding concentrations were 1,665+/-498 ng/ml and 1,256+/-379 (p<0.001). The adjusted odds ratio for spirometrically diagnosed COPD in heterozygotes versus noncarriers was 0.5 (95% confidence interval: 0.3-0.9). After stratification, the equivalent adjusted odds ratio was 1.5 (0.3-6.6) among nonsmokers and 0.4 (0.2-0.8) among smokers (p value for interaction=0.10). The adjusted hazard ratio for COPD hospitalization or death during follow-up in heterozygotes versus noncarriers was 0.3 (0.1-0.8).
Extracellular superoxide dismutase R213G heterozygosity protects against development of COPD in the Danish general population. This was observed in smokers, but not in nonsmokers.
氧化应激增加与慢性阻塞性肺疾病(COPD)有关;然而,血浆和支气管衬液中含有抗氧化剂细胞外超氧化物歧化酶。约2%的白人个体在编码细胞外超氧化物歧化酶的基因中携带R213G多态性,这使血浆细胞外超氧化物歧化酶增加10倍,并且推测也会使支气管衬液中的细胞外超氧化物歧化酶含量升高。
我们检验了R213G降低COPD风险的假设。
我们对来自丹麦普通人群的9258名个体进行了R213G基因分型的横断面和前瞻性(24年期间)研究。
我们测定了血浆细胞外超氧化物歧化酶浓度、肺功能以及通过肺活量测定法或国家住院和死亡登记册诊断的COPD。
在普通人群中,97.5%为非携带者,2.4%为杂合子,0.02%为纯合子。在R213G非携带者中,有COPD和无COPD个体的血浆细胞外超氧化物歧化酶浓度分别为148±52和142±43 ng/ml(均值±标准差)(学生t检验,p = 0.02)。在杂合子中,相应浓度分别为1665±498 ng/ml和1256±379(p<0.001)。杂合子与非携带者相比,经肺活量测定法诊断的COPD的校正比值比为0.5(95%置信区间:0.3 - 0.9)。分层后,在不吸烟者中,等效校正比值比为1.5(0.3 - 6.6),在吸烟者中为0.4(0.2 - 0.8)(交互作用p值 = 0.10)。杂合子与非携带者相比,随访期间COPD住院或死亡的校正风险比为0.3(0.1 - 0.8)。
在丹麦普通人群中,细胞外超氧化物歧化酶R213G杂合性可预防COPD的发生。这在吸烟者中观察到,但在不吸烟者中未观察到。